Health Care · Medicinal Chemicals & Botanical Products · Nasdaq · CIK 1056358 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $4.88Day +1.24%Mkt cap $9M1Y −47.1%Off 52W high −60.8%Vol (1Y) 92.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.8% of sh out |
| Days to cover2.6d |
| 13F net flow (QoQ)−0.12% |
| Top-10 13F concentration99.8% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$108.0M |
| Earnings (TTM)-$12.7M |
| Net margin−14.1% |
| Total debt / EBITDA4.13× |
| Sales growth 3Y−7.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−40.8% |
| 1Y−47.1% |
| 3Y−59.0% |
| 5Y−79.3% |
| 10Y−60.9% |
| Since incept. (ann.)−14.0% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)92.0% |
| Ann. volatility (3Y)78.5% |
| Sharpe (1Y)−0.28 |
| Sharpe (3Y)0.00 |
| Max drawdown (1Y)−61.2% |
| Max drawdown (3Y)−74.9% |
| Beta (3Y vs SPY)0.02 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 52,163 | $301,502 | 2.70% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 49,617 | $297,702 | 2.57% | new |
| RENAISSANCE TECHNOLOGIES LLC | 30,878 | $178,475 | 1.60% | −2.8% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 28,954 | $173,724 | 1.50% | +0.0% |
| DIMENSIONAL FUND ADVISORS LP | 11,925 | $71,550 | 0.62% | −5.9% |
| ACADIAN ASSET MANAGEMENT LLC | 7,741 | $46,000 | 0.40% | +0.0% |
| VANGUARD FIDUCIARY TRUST CO | 2,679 | $16,074 | 0.14% | new |
| UBS Group AG | 485 | $2,804 | 0.03% | +1.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $0.49 | — | $24.9M | −6.2% |
| 2025-09-30 | 2025-11-12 | $1.01 | — | $29.2M | −8.1% |
| 2025-03-31 | 2025-05-13 | −$0.80 | −227.0% | $26.6M | −9.6% |
| 2024-12-31 | 2025-03-26 | — | — | $29.0M | −11.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 98% · Product And Service Other 1% · Associate Service Fees 0%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
